- What the 85% Figure Actually Means
- What Not to Conclude From It
- Why There Is No 2026 Pass Rate
- Who Gets to Sit: The Four Eligibility Routes
- Exam Format and Logistics
- Where the Points Are: Domain Weights
- Fees: A Source Conflict You Should Know About
- Do Not Confuse C-cert Numbers With Pass Rates
- Using the Data to Plan Your 2027 Attempt
- Frequently Asked Questions
- UCNS reports an 85% historical average initial NO pass rate, with no disclosed cohort range or denominator.
- That 85% is not a 2025 or 2026 figure, and no 2026 initial NO exam is offered.
- The next published NO sitting is December 6-10, 2027; applications open March 1, 2027.
- Adult tumors carry 35% of the exam; pediatric tumors and systemic cancer-related disorders each carry 25%.
What the 85% Figure Actually Means
Anyone searching for a Neuro-Oncology Certification pass rate will eventually land on one number: the United Council for Neurologic Subspecialties (UCNS) publishes an 85% historical average initial NO pass rate on its official certification statistics page. That is the only pass-rate figure in the official materials we reviewed, and it deserves careful reading before you build any expectations on it.
Three things about that number are worth stating plainly:
- It is a historical average. It aggregates results across past administrations rather than describing a single sitting.
- No cohort range is disclosed. We cannot tell whether individual administrations ran higher or lower than 85%, or how much they varied.
- No denominator is disclosed. The published statistics do not tell us how many candidates the average represents, which matters because neuro-oncology is a small subspecialty and small cohorts can swing widely.
What Not to Conclude From It
Pass-rate statistics invite over-interpretation. Here are the most common mistakes, and why the data does not support them.
Mistake 1: Treating 85% as the 2026 (or 2025) pass rate
The figure is not tied to any specific year. Pages that present "the 2026 NO pass rate" are either mislabeling the historical average or inventing a number. Neither is useful to you.
Mistake 2: Reading it as a statement about difficulty
A high pass rate for a subspecialty exam usually reflects who sits, not how easy the exam is. Candidates must already hold a qualifying primary board certification and an unrestricted license, and they must complete one of four credentialing routes before they are approved to test. By the time someone reaches the exam room, they have been filtered by training and practice history. A high pass rate in a pre-screened pool is entirely compatible with a demanding exam.
Mistake 3: Inferring a passing score
A numerical initial-exam passing score is not publicly verified. UCNS describes expert standard setting and post-exam psychometric review, which means the cut point reflects a judgment about minimum competence rather than a fixed percentage you can target. Our companion piece NO Passing Score 2026: Exactly What You Need to Pass covers what is and is not known.
Mistake 4: Assuming first-time and repeat takers are separate
The published statistic is labeled as the initial NO pass rate, but without a denominator or breakdown we cannot say how first-attempt versus repeat performance contributes. Do not quote subgroup figures that the source does not provide.
Why There Is No 2026 Pass Rate
This is the single most important scheduling fact behind the headline of this article. The Neuro-Oncology initial examination is administered biennially in odd-numbered years. There is no initial NO sitting in 2026, so there is no 2026 initial-exam pass rate to report, now or later.
The next published sitting is December 6-10, 2027. The application calendar around it is:
| Milestone | Published Date |
|---|---|
| Applications open | March 1 |
| Standard application deadline | June 1 |
| Extended deadline (adds a $500 late fee) | June 15 |
| Approved candidates schedule their appointment | July 19 through November 22 |
| Examination week | December 6-10, 2027 |
For the full scheduling picture, including how the testing window works, see NO Exam Dates 2026: Testing Windows, Deadlines & Scheduling. The practical upshot: because the exam is offered only every other year, a missed application deadline can cost you two years, which makes preparation timing at least as consequential as any pass-rate statistic.
Who Gets to Sit: The Four Eligibility Routes
Because the pass rate describes a screened population, it helps to understand the screen. General eligibility requires a qualifying ABMS certification (or AOA/RCPSC equivalent) in neurology, child neurology, neurological surgery, internal medicine and medical oncology, pediatrics and pediatric hematology-oncology, or radiation oncology, plus current unrestricted licensure in the United States, its territories, or Canada and in each jurisdiction of practice.
On top of that, candidates complete one of four alternative routes, not all four:
| Route | Core Requirement |
|---|---|
| 1. UCNS-Accredited Fellowship | At least 12 months of NO fellowship; apply within 48 months of completion; director verification or completion certificate |
| 2. Practice Track | At least 36 months after residency with at least 25% of professional time in NO within the prior 60 months, plus one of: 12+ months of formal non-accredited NO training, 50+ NO-specific AMA PRA Category 1 CME hours in the prior 60 months, or a full-time academic appointment teaching NO |
| 3. Academic Appointment at a UCNS-Accredited Program | Full-time faculty appointment teaching NO fellows, chair verification, and the practice-time and practice-pattern requirements |
| 4. Internationally Trained Faculty at UCNS-Accredited Programs | Active program-director/faculty appointment or written offer, chair verification that passing is a condition of appointment, and documentation of the required practice period |
Exam Format and Logistics
Knowing the format helps you judge what a given pass rate is actually measuring. The initial NO exam consists of:
- 200 multiple-choice questions delivered in four hours.
- A closed-book format in two parts, separated by a 15-minute structured break. Once you submit a part, you cannot return to it.
- A split between scored and pretest items that is not publicly specified in the retrieved official materials.
- Two testing modalities: Meazure Learning test centers (available since January 1, 2025) or live online proctoring through ProctorU. Older remote-only instructions are superseded.
Remote candidates should budget extra appointment time beyond the four hours, because equipment and workspace checks, the required Guardian browser, and the break all add to the session. Results arrive after processing rather than immediately, so do not plan around an on-the-spot score.
The no-return rule between parts is worth rehearsing. It changes pacing: you cannot bank hard questions for a second pass in the final minutes of a part, so decisive first-pass answering matters more here than on exams that allow free navigation.
Where the Points Are: Domain Weights
Even without a disclosed passing score, the content outline tells you where the exam's weight sits. The currently linked outline is the version revised October 10, 2018; it is not a newly issued 2026 blueprint, so treat it as the best available official guide rather than a fresh release.
Domain 1: Adult Primary Nervous System Tumors (35%)
The largest slice of the exam. Coverage includes diagnostic methods and treatment approaches.
- Diagnostic methods: clinical history and examination, laboratory testing, imaging, neuropathology, and other neurodiagnostic procedures
- Standard, experimental, and medical neuro-oncologic therapies
Domain 2: Pediatric Primary Nervous System Tumors (25%)
Structured like the adult domain, but for pediatric tumor biology and management.
- Diagnostic methods across history, laboratory, imaging, neuropathology, and neurodiagnostics
- Standard, experimental, and medical therapies in children
Domain 3: Metastatic Cancer to the Nervous System (15%)
The smallest domain, but a focused one.
- Brain and spinal cord metastases, skull base disease, and leptomeningeal disease
- Epidural disease, plexus and peripheral nerve involvement, and spinal cord compression
Domain 4: Systemic Cancer-Related Neurologic Disorders (25%)
A broad domain that reaches well beyond tumors themselves.
- Toxic, nutritional, and metabolic encephalopathy; central and systemic infections; cerebrovascular disease
- Paraneoplastic syndromes, adverse effects of surgery, drugs, and radiation, seizures, and raised intracranial pressure
- Venous thrombosis, neutropenia/thrombocytopenia/anemia, blood products and growth-factor support, and transplantation-related neurologic complications
- Pain and headache care, plus palliation and end-of-life care
A small wording note: the detailed section heading in the outline reads "Systemic Cancer-Related Neurologic Disorders," while the summary table prints "Systematic Cancer-Related Neurologic Disorders." This is an internal discrepancy in the source document, so do not be thrown if you see both spellings. For the topic-by-topic breakdown, read NO Exam Domains 2026: Complete Guide to All 4 Content Areas.
Key Takeaway
Pediatric tumors and systemic cancer-related disorders together account for half of the exam. Candidates from adult-focused practices who skim those two domains are leaving a large share of the blueprint under-prepared, regardless of how strong the historical pass rate looks.
Fees: A Source Conflict You Should Know About
Cost belongs in any honest discussion of pass rates, because a retake means paying again and, given the biennial schedule, waiting two years. Here the official sources do not agree with each other:
- The general UCNS certification fee schedule and FAQ publish $1,700 total: a $680 nonrefundable application fee plus a $1,020 examination fee, with no member/non-member price tiers.
- Eligible graduates of UCNS-accredited fellowships receive a $250 discount when applying within 48 months, provided the program was accredited at completion.
- However, the undated exact NO store product (EX_NO_I) displays $2,200.
The official pages do not explicitly reconcile this difference, so we do not present either amount as an uncontested current checkout price. Verify the figure on your actual application invoice before budgeting. Our NO Certification Cost 2026: Complete Pricing Breakdown tracks this conflict in more detail, and Is the NO Certification Worth It? Complete ROI Analysis 2026 places the cost in a longer-term context.
Do Not Confuse C-cert Numbers With Pass Rates
A frequent source of bad data is mixing up initial certification with Continuous Certification (C-cert). They are different activities with different rules.
| Feature | Initial NO Exam | C-cert Quiz |
|---|---|---|
| Format | 200 multiple-choice questions, four hours, closed-book, proctored | 25 questions, 100 minutes, open-article, unproctored |
| Passing standard | Numerical score not verified; expert standard setting | 80% required |
| Attempts | Per application cycle | Up to three |
| Frequency | Biennial, odd-numbered years | Annual |
UCNS has also published a 2025 C-cert average score. That is a separate statistic and is not an initial-exam pass rate. Likewise, the 80% threshold is a quiz requirement, not evidence of how hard the initial exam is.
For context on what follows certification: validity is maintained through annual C-cert beginning the calendar year after initial certification. You must maintain your primary board certification and unrestricted license, read the annual list of up to ten articles or guidelines, pay the $175 annual fee per subspecialty ($150 if paid by June 1), and pass that year's quiz by December 31. Two consecutive years of noncompliance lead to loss of certification. The legacy ten-year renewal model is no longer the current rule. The 2026 NO C-cert reading list is continuing-certification material, not a replacement initial-exam blueprint.
Using the Data to Plan Your 2027 Attempt
Since no sitting occurs in 2026, the useful question is how to spend the time before the December 2027 exam. One brief, NO-specific scheduling approach, built around the domain weights:
Anchor on the heaviest domain
- Start with Domain 1 (35%): adult tumor diagnostics, neuropathology, imaging, and therapy classes
Close the pediatric and systemic gap
- Give Domains 2 and 4 (25% each) dedicated blocks, especially if your practice is adult-heavy or tumor-only
- Cover paraneoplastic syndromes, treatment complications, and palliative care explicitly
Metastatic disease and timed practice
- Review Domain 3 (15%): leptomeningeal disease, epidural disease, and cord compression
- Run 100-question blocks with a 15-minute break to rehearse the no-return, two-part format
For a fuller plan, see NO Study Guide 2026: How to Pass on Your First Attempt, and keep NO Cheat Sheet 2026: One-Page Review of Must-Know Facts handy for last-week review. When you are ready to test yourself against blueprint-style questions, our NO practice test lets you drill by domain, and you can return to the main practice site to track weak areas over time.
Frequently Asked Questions
UCNS's official certification statistics report an 85% historical average initial NO pass rate. The figure has no disclosed cohort range or denominator, and it is not specific to 2025 or 2026.
No. The initial NO exam is offered biennially in odd-numbered years, so there is no 2026 initial sitting. The next published sitting is December 6-10, 2027.
No. The 80% threshold applies to the annual 25-question, open-article C-cert quiz used for renewal. It does not describe the initial exam, and it is not a pass rate. A numerical initial-exam passing score has not been verified.
A numerical passing score is not publicly verified. UCNS describes expert standard setting and post-exam psychometric review rather than a fixed percentage. See the passing-score guide for what is known.
The general UCNS fee schedule lists $1,700 total ($680 application plus $1,020 exam), while the NO store product page shows $2,200. The official pages do not reconcile this, so verify the amount on your application invoice. A $250 discount may apply to eligible fellowship graduates.